GLP 1 coverage worries keep half of untreated adults with obesity from starting in a new survey

Half of adults with obesity who have never taken a GLP 1 drug say they worry insurance will not pay or the price will be too high. Those GLP 1 coverage worries come from a new Everyday Health survey of 858 people, which also found that one in three past users stopped for reasons tied to cost and coverage. The poll was run online from August 5 to 15, 2026, and published on October 27. It is a publisher survey, not a peer reviewed study, but it lines up with what doctors describe as plans change their rules.

What the survey asked

Everyday Health surveyed 858 people who either have obesity or take a GLP 1 drug for weight loss without a chronic disease diagnosis, according to the Everyday Health survey report by health writer Jessica Migala. The questions covered why people hold back from starting, what worries those already on treatment, and why past users quit. The article gives the sample size and the field dates. It does not say how respondents were recruited or whether the results were weighted to match the wider population, so the percentages describe this group of respondents rather than every American with obesity. Even so, the answers give a rare look at money as a barrier, measured from the side of the patient rather than the plan.

The biggest worry among people already taking a GLP 1 drug was keeping weight off over the long term, named by about four in ten. More than one in three worried about what would happen if they stopped. Among people with obesity who had never used the drugs and did not plan to start within six months, 53% said they did not want to rely on a medicine for weight control over the long term. Side effects also weighed on respondents. Some 37% said online health content offered too little guidance on long term side effects, and among current users with obesity, 28% had dealt with nausea or vomiting while 42% reported diarrhea and constipation.

GLP 1 coverage worries before the first dose

Cost sits near the top of the list of reasons not to begin. One in two people with obesity who had never taken a GLP 1 said they feared their insurer would not cover it or that it would cost too much. Kimberly Gudzune, an obesity medicine physician and affiliate faculty member at the Johns Hopkins Bloomberg School of Public Health, told Everyday Health that coverage is the most common problem she sees. "The most common challenge I see are issues related to insurance coverage, particularly as employers and insurance companies are changing the eligibility criteria for coverage, increasing copays, or even eliminating coverage," she said. That matches the direction of recent plan decisions across the country.

One in two people with obesity who had never taken a GLP 1 said they feared their insurer would not cover it or that it would cost too much.

Peptide Town has tracked several of those decisions this year. In Massachusetts, weight loss coverage halved after insurers pulled back. At Walmart, the company plan now makes Ozempic and Mounjaro free for diabetes while leaving out weight loss, as reported in our story on Walmart GLP 1 coverage. Rules like these split patients by diagnosis. A person with type 2 diabetes is often covered, while a person with obesity alone may face the full cash price. The survey does not ask which plans respondents had, so it cannot link a worry to a specific rule. It does show that the fear of a bill shapes the decision before any prescription is written.

Stopping for cost and what doctors advise

The worry is not only about starting. One in three past users told the survey they had stopped for reasons linked to cost and coverage. Gudzune called these coverage changes "devastating" for many patients who would otherwise want to stay on treatment. Her advice to people in that position is to go back to the prescriber and ask about alternatives. "There may be a lower-cost alternative medication that can be used, particularly the older medications that are not GLP-1s," she said. Devika Umashanker, system director for medical weight loss at Hartford HealthCare Digestive Health Institute, said the decision to stay on a drug should be revisited regularly and should weigh cost and access along with results and side effects.

Stopping has a known downside, which is why a forced stop matters. The Everyday Health article cites a BMJ review and meta-analysis published in January 2026 that projects people would return to their starting weight about a year and a half after stopping semaglutide or tirzepatide. Umashanker compared these drugs to medicines for high blood pressure and diabetes, whose benefits generally last only while treatment continues. For a patient whose plan stops paying, that means a choice between a cash bill, a switch to an older drug, or losing the effect. The table below lists the main survey figures on cost, worries and side effects as Everyday Health reported them.

Who is affected and what to watch

For patients, GLP 1 coverage worries are a reason to check coverage before starting, including whether the plan covers weight loss or only diabetes, and what happens at renewal. Plans can change eligibility rules, copays or the whole benefit from one year to the next, as Gudzune described. A patient who loses cover mid treatment can ask the prescriber about other approved options before stopping abruptly. For prescribers, the findings suggest that cost belongs in the first conversation, not only side effects. A patient who expects to lose coverage within months may need a different plan from the start, and Umashanker said obesity care can also include nutrition support, activity, behavioral treatment, other medicines or surgery.

For payers and employers, the survey shows the human side of decisions that are usually framed as budget lines. When cover ends, some patients stop, and the weight they lost tends to return, which can bring back the conditions the drug was meant to ease. Whether that trade makes sense is a question each plan answers differently. The survey cannot settle it, and its numbers come from one publisher poll with limited method details. Readers who want to follow which plans pay for these drugs and on what terms can find every update on our page about who pays and how, including public programs and employer plans.

Conclusion

GLP 1 coverage worries stop half of the untreated adults with obesity in this survey from starting, and cost or coverage pushed one in three past users to quit. The poll is not peer reviewed and lacks full method details, but it fits a year of tighter plan rules. Before starting or stopping, check what your plan covers and ask your prescriber about approved alternatives.